It has been observed that G9a is overexpressed in a number of cancers, including esophageal squamous cell carcinoma, hepatocellular carcinoma, aggressive lung cancer, brain cancer, multiple myeloma, and aggressive ovarian carcinoma (Figure 5) (76–79). Here, EHMT2 is linked to ovarian carcinoma.